News and Trends 16 Aug 2019 First Potential Chlamydia Vaccine Shows Early Promise A vaccine targeting the sexually transmitted infection chlamydia, which would be the first of its kind if approved, has proved safe and able to stimulate the immune system in a phase I trial. In the phase I trial, the vaccine was injected into 35 healthy women. Blood samples from the volunteers were then measured to […] August 16, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 4 Jun 2019 Ultra-Fast Diagnostics Could Transform Sexual Health Each day more than one million people around the world acquire sexually transmitted infections, with a profound impact on sexual and reproductive health across the globe. Biotechs across Europe are developing rapid diagnostics for some of the most common STIs. It’s difficult to comprehend the sheer scale of the number of people affected by sexually […] June 4, 2019 - 7 minutesmins - By David Cox Share WhatsApp Twitter Linkedin Email
Interview 25 Apr 2019 European Biotechnology in 2019 and Beyond: What’s Hot and What’s Not? We spend a lot of time focusing on specific developments in biotechnology, but sometimes it’s good to take a step back and look at the bigger picture. With this in mind, I asked three experts at our recent Refresh event in Vienna to share what is hot in European biotech right now and what trends […] April 25, 2019 - 11 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 8 Mar 2019 Flu Resistant to Antivirals? This Biotech Has a Drug for That We are visiting the medieval German city of Tübingen this week. It hosts the biotech Atriva Therapeutics, which is developing antiviral drugs for influenza that can circumvent drug resistance. Mission: To make antiviral drugs that, unlike conventional drugs, target the host cell instead of the virus. This can prevent the virus from building resistance to […] March 8, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 1 Mar 2019 Rapid Response mRNA Vaccine Facility Gets €30M Funding An mRNA vaccine facility, run by the German biotech CureVac, has received a €30M development grant to rapidly manufacture vaccines for regions hit by outbreaks of rabies, yellow fever and emerging diseases. CureVac is a company that develops vaccines made of mRNA, a molecule that lets cells translate genes into proteins. The company’s drug candidates […] March 1, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 18 Feb 2019 Tuberculosis Treatment Kills Bacteria with Their Own Suicide Toxin A European academic research collaboration has found a new potential weapon against antibiotic-resistant tuberculosis: its own toxins. Many types of bacteria, such as the pathogen responsible for the deadly lung disease tuberculosis, Mycobacterium tuberculosis, use toxins to stay alive. For example, these toxins can be useful when the bacteria are starved or infected by viruses, […] February 18, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2018 Llama Antibodies Could Be the Key to Universal Flu Prevention Researchers have developed a new approach to prevent the flu that can protect against all seasonal strains of the virus. It also has potential to be effective for those that cannot get vaccinated. In a paper published in Science today, researchers at Janssen and The Scripps Research Institute have revealed a new approach to prevent […] November 1, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 1 Oct 2018 Could These Innovative Flu Vaccines Prevent Deaths From Deadly Outbreaks? Despite more than a century of scientific endeavour, influenza remains one of the most deadly infectious diseases worldwide. Across Europe, many biotechs are working on novel solutions that could dramatically improve the protection rates offered by current vaccines. Some may even lead to the holy grail of influenza research – a universal flu vaccine. Each […] October 1, 2018 - 8 minutesmins - By David Cox Share WhatsApp Twitter Linkedin Email
News and Trends 7 Aug 2018 Update: Seaweed-Derived Treatment for Common Cold Approved in the EU Update (07/08/2018): Marinomed Biotech has obtained EU approval to sell a nasal spray containing a polymer derived from red seaweed that can trap most common cold viruses to stop them from infecting us. Published on 19/07/2018 Marinomed Biotech’s antiviral treatment, which is derived from seaweed, could be used to treat the cause of respiratory […] August 7, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 1 Aug 2018 London Biotech Raises €47M to Develop First Treatment Against RSV Virus ReViral will dedicate the funds to run two clinical trials to test whether its antiviral can help patients at high risk from RSV infections. The respiratory syncytial virus (RSV) only causes mild cold symptoms in most people. But for small children and immunosuppressed patients, it can be deadly. “There are at present no approved therapies […] August 1, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2018 People with Innate Resistance to HIV Could Provide a Functional HIV Cure In the process of studying HIV-infected patients who naturally don’t need therapy to control the virus, scientists have found what could become a functional cure for HIV infections. A team of researchers from France, Italy, the UK and Australia has identified a molecule that could be transferred to HIV-positive people to help […] June 8, 2018 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2018 Another Pneumonia Antibiotic is Close to Treating Patients Nabriva Therapeutics has obtained positive Phase III results for its antibiotic lefamulin and plans to seek FDA approval for the drug by the end of this year. Nabriva Therapeutics has obtained a second round of positive Phase III results for lefamulin, its antibiotic targeting community-acquired pneumonia. The drug was shown to be as effective as […] May 23, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email